⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
BRTX News
BioRestorative Therapies, Inc. Common Stock (NV)
BioRestorative Announces Pricing of $5.0 Million Public Offering
globenewswire.com
BRTX
BioRestorative Announces Positive Outcome from Type B Meeting with FDA
globenewswire.com
BRTX
BioRestorative Completes Patient Enrollment in Landmark Phase 2 Trial of BRTX-100 for Chronic Lumbar Disc Disease
globenewswire.com
BRTX
BioRestorative Granted Type B Meeting with FDA to Discuss Accelerated BLA Approval Pathway for BRTX-100 in Chronic Lumbar Disc Disease
globenewswire.com
BRTX
BioRestorative Therapies Reports Third Quarter 2025 Financial Results and Provides Business Update
globenewswire.com
BRTX
BioRestorative Therapies to Report Third Quarter 2025 Financial Results and Host Conference Call on November 12, 2025
globenewswire.com
BRTX
BioRestorative Awarded Notice of Allowance for Japanese Patent – Expands Protection for Potential Cell-Based Alternative to Multi-Billion Dollar GLP-1 Drug Market
globenewswire.com
BRTX
BioRestorative Therapies to Participate in the 2025 Maxim Growth Summit
globenewswire.com
BRTX
BioRestorative CEO Lance Alstodt Interviewed on “The Big Biz Show”
globenewswire.com
BRTX
BioRestorative Therapies Announces $1.085 Million Registered Direct Offering Priced Above Market
globenewswire.com
BRTX